SCHEMBL5523141

SCHEMBL5523141

O=C1CCC(OCc2ccccc2F)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.52
PRMT6 Q96LA8 1/20 0.52
IDO1 P14902 2/20 0.44
KCNH2 Q12809 8/20 0.43
SCN5A Q14524 6/20 0.43
MAOB P27338 2/20 0.41
TACR1 P25103 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
SCN3A Q9NY46 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11013665 0.91 CARM1 (0.47) CARM1PRMT6IDO1KCNH2SCN5A
SCHEMBL18615766 0.83 CARM1 (0.57) CARM1PRMT6IDO1KCNH2SCN5A
SCHEMBL3128665 0.79 CARM1 (0.53) CARM1PRMT6IDO1KCNH2SCN5A
SCHEMBL19921471 0.79 SLC6A2 (0.57) CARM1PRMT6IDO1KCNH2MAOB
SCHEMBL5532610 0.78 IDO1 (0.42) IDO1KCNH2SCN5AMAOBALDH1A1
Hydrochloric Acid SCHEMBL1476112 0.77 SLC6A2 (0.56) CARM1PRMT6IDO1KCNH2MAOB
SCHEMBL11010221 0.77 IDO1 (0.44) CARM1PRMT6IDO1KCNH2SCN5A
SCHEMBL7332875 0.76 CARM1 (0.69) CARM1PRMT6IDO1KCNH2SCN5A
SCHEMBL416422 0.76 OPRM1 (0.50) CARM1PRMT6
SCHEMBL11304094 0.75 IDO1 (0.53) CARM1PRMT6IDO1KCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
EP-1716100-A2 THERAPEUTIC AMIDE DERIVATIVES Pfizer, Inc. (US) 2006-11-02 EP disclosed
WO-2005080317-A2 THERAPEUTIC AMIDE DERIVATIVES PFIZER JAPAN, INC. (JP) 2005-09-01 WO disclosed
WO-2005080317-A2 THERAPEUTIC AMIDE DERIVATIVES PFIZER JAPAN, INC. (JP) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167452-A1 Therapeutic amide derivatives GRIN1, GRIN2B, GRIN3A CARM1 1945/4885PRMT6 1988/4885IDO1 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.